CRISPR Therapeutics

We have established a diverse portfolio across a broad range of disease areas including hemoglobinopathies, oncology, diabetes and cardiovascular disease. CASGEVY™ (exagamglogene autotemcel), a CRISPR/Cas9 gene-edited therapy arising out of our collaboration with Vertex Pharmaceuticals Incorporated, is approved in some countries for certain eligible patients with sickle cell disease or transfusion-dependent beta thalassemia. We take pride in delivering outstanding work, and it's an honor to have our efforts recognized. Our awards celebrate innovation, dedication, and excellence in our industry. Here are some of the accolades we've earned along the way.